Table 1.
Subject characteristics.
| Younger | At Risk | |
|---|---|---|
| Sex (M/F) | 6 / 6 | 3 / 3 |
| Age (y) | 25 ± 3 (19 – 32) | 67 ± 4 Y (62 – 74) |
| Height (cm) | 173 ± 13 (157 – 204) | 167 ± 9 (158 – 183) |
| Weight (kg) | 77.6 ± 13.1 (59.5 – 104.0) | 78.1 ± 12.8 (57.4 – 97.2) |
| Body surface area (m2) | 1.9 ± 0.2 (1.6 – 2.4) | 1.9 ± 0.1 (1.7 – 2.0) |
| Sum of skinfolds (mm) | 137 ± 53 (61 – 210) | 156 ± 54 (100 – 230) |
| Body fat (%) | 26 ± 13 (8 – 47) | 30 ± 13 (20 – 50) |
| Prescription medications (n) | 0 | 6 Y |
| Hypertension (ANGII antagonists/ACE inhibitors) | 0 | 3 (2/1) |
| Type II Diabetes (metformin) | 0 | 2 |
| Hypercholesteremia (statins) | 0 | 5 |
| Screening heart rate (bpm) | 64 ± 11 (52 – 88) | 62 ± 10 (48 – 72) |
| Screening systolic blood pressure (mmHg) | 118 ± 9 (106 – 138) | 136 ± 7 Y (130 – 148) |
| Screening diastolic blood pressure (mmHg) | 72 ± 9 (60 – 90) | 78 ± 15 (58 – 102) |
| Screening mean arterial pressure (mmHg) | 88 ± 8 (76 – 101) | 97 ± 11 Y (77 – 117) |
| Physical activity (high/moderate/low) a | 4 / 7 / 1 | 3 / 3 / 0 |
| Montreal Cognitive Assessment Score b | 29 ± 2 (26 – 30) | 27 ± 1 Y (26 – 27) |